Folding proteins in fatal ways

Nature

Volumn 426, Issue 6968, 2003, Pages 900-904

  Selkoe, Dennis J ^a  

^a Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DEPOSITION; DISEASE CONTROL; DRUG THERAPY; NEUROLOGY; PATHOLOGY;

EXTRACELLULAR DEPOSITS; NEURONS;

PROTEINS;

PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; CELL DISRUPTION; CELL FUNCTION; CYTOTOXICITY; EXTRACELLULAR SPACE; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW;

AMYLOIDOSIS; HUMANS; NEURODEGENERATIVE DISEASES; ORGAN SPECIFICITY; PROTEIN FOLDING; PROTEINS;

EID: 0347987853     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02264     Document Type: Review

References (26)

1. Glenner G. G. Amyloid deposits and amyloidosis: the β-fibrilloses (first of two parts). N. Engl. J. Med. 302, 1283-1292 (1980).
2. Glenner, G. G. Amyloid deposits and amyloidosis: the β-fibrilloses (second of two parts). N. Engl. J. Med. 302, 1333-1343 (1980).
3. Fandrich, M., Fletcher, M. A. & Dobson, C. M. Amyloid fibrils from muscle myoglobin. Nature 410, 165-166 (2001).
4. Bucciantini, M. et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511 (2002).
5. Dobson, C. M. The structural basis of protein folding and its links with human disease. Phil. Trans. R. Soc. Lond. B 356, 133-145 (2001).
6. Jarrett, J. T. & Lansbury, P. T. Seeding 'one-dimensional crystallization' crystallization' of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058 (1993).
7. Perutz, M. F. & Windle, A. H. Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412, 143-144 (2001).
8. Zoghbi, H. Y. & Orr, H. T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
9. Selkoe, D. J. & Podlisny, M. B. Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet. 3, 67-99 (2002).
10. Hutton, M. Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 56, S21-S25 (2001).
11. Prusiner, S. B. Neurodegenerative diseases and prions. N. Engl. J. Med. 344, 1516-1526 (2001).
12. Booth, D. R. et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793 (1997).
13. Haezebrouck, P. et al. An equilibrium partially folded state of human lysozyme at low pH. J. Mol. Biol. 246, 382-387 (1995).
14. Radford, S. E. & Dobson, C. M. Insights into protein folding using physical techniques: studies of lysozyme and α-lactalbumin. Phil. Trans. R. Soc. Lond. B 348, 17-25 (1995).
15. Riek, R. et al. NMR structure of the mouse prion protein domain PrP(121-231). Nature 382, 180-182 (1996).
16. Hsia, A. Y. et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad. Sci. USA 96, 3228-3233 (1999).
17. Mucke, L. et al. High-level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058 (2000).
18. Naslund, J. et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. J. Am. Med. Assoc. 283, 1571-1577 (2000).
19. Kuo, Y.-M. et al. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077-4081 (1996).
20. Lue, L. F. et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862 (1999).
21. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002).
22. Walsh, D. et al. Naturally secreted oligomers of the Alzheimer amyloid β-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
23. Watase, K. et al. Along CAG repeat in the mouse Sca 1 locus replicates SCA 1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905-919 (2002).
24. Auluck P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M. & Bonini, N. M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868 (2002).
25. Warrick, J. M. et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nature Genet. 23, 425-428 (1999).
26. Opal, P. & Zoghbi, H. Y. The role of chaperones in polyglutamine disease. Trends Mol. Med. 8, 232-236 (2002).